AstraZeneca’s chief executive Pascal Soriot said on Sunday that the British pharmaceutical company’s vaccine was believed to be effective against new coronavirus strains found in the UK.
“So far, we think the vaccine should be effective. “But, we can’t be sure, so we’ll test it,” Soriot said when asked how the vaccine could be caught against the new strain of the virus.
According to Associated Press reports, Soriat told the Sunday Times that researchers for AstraZeneca had found a “winning formula” to make its formula as effective as Pfizer or Moderna, both of which have already been approved. The AP notes that the AstraZeneca vaccine is expected to be approved this week.
“We think we’ve found the winning formula and how to get efficacy, after two doses, is there with everyone else,” Soriot said.
The AstraZeneca vaccine, developed in partnership with Oxford University, was not initially thought to be as effective as its American counterparts, with partial results indicating that it is 70 percent effective in preventing illness, according to AP reports.
This new strain of the virus has sounded the alarm as many countries have restricted or banned travel from the UK, not considered to be more lethal or causal. More severe symptoms.
Moderna said last week that it believes its vaccine can effectively protect people from new strains.
One of the main differences between the AstraZeneca vaccine is that unlike the Moderna and Pfizer vaccines, it is not an MRNA vaccine. According to the Centers for Disease Control and Prevention, the vaccine teaches the immune system how to make certain proteins that then respond to the immune system without entering the actual virus into the body..
The AstraZeneca vaccine uses a weaker version of the virus to teach the immune system how to suppress it.
The UK was the first Western country to approve the coronavirus vaccine, which approved the Pfizer vaccine in early December. As of December 24, more than 600,000 have been vaccinated in the UK, the AP reports.
.
